Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and DDI of CG100650 (Polmacoxib + Tramadol) in Healthy Volunteers
NCT03775629Phase 1Completed
- Sponsor
- Crystal Genomics
- Start
- Dec 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in acute pain and chronic pain comparing Polmacoxib + Tramadol, Polmacoxib and Tramadol (3 arms). Primary endpoints: Area Under the Curve over the dosing interval (AUCtau) at 4 weeks and Maximum Plasma Concentration (Cmax) at 4 weeks. Started Dec 2018; status: completed.
02
Drugs
polmacoxibtramadol
03
Conditions
acute painchronic pain
Beyond the preview
Go deeper on NCT03775629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03775629.